Escudero-Vilaplana V - Search Results

1

Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer.

Escudero-Vilaplana V, Bernal E, Casado G, Collado-Borrell R, Diez-Fernández R, Fernández Román AB, Folguera C, González-Cortijo L, Herrero-Fernández M, Marquina G, Martínez Nieto C, Rodríguez MA, Rubio AR, Sanmartin-Fenollera P, Vazquez Castillo MJ, Comellas M, Guerra EM. Escudero-Vilaplana V, et al. Front Oncol. 2022 May 18;12:885910. doi: 10.3389/fonc.2022.885910. eCollection 2022. Front Oncol. 2022. PMID: 35664764 Free PMC article.

2

Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis.

Escudero-Vilaplana V, Martínez-Nieto C, López-Gómez JM, Vega-Martínez A, Bellón-Cano JM, Sanjurjo-Sáez M. Escudero-Vilaplana V, et al. Int J Clin Pharm. 2013 Jun;35(3):463-8. doi: 10.1007/s11096-013-9774-z. Epub 2013 Apr 18. Int J Clin Pharm. 2013. PMID: 23595914

3

Smartphone applications for cancer patients; what we know about them?

Collado-Borrell R, Escudero-Vilaplana V, Ribed-Sánchez A, Ibáñez-García S, Herranz-Alonso A, Sanjurjo-Sáez M. Collado-Borrell R, et al. Farm Hosp. 2016 Jan 1;40(1):25-35. doi: 10.7399/fh.2016.40.1.8993. Farm Hosp. 2016. PMID: 26882831

4

Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.

Collado-Borrell R, Escudero-Vilaplana V, Romero-Jiménez R, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Sáez M. Collado-Borrell R, et al. J Cancer Res Clin Oncol. 2016 Nov;142(11):2319-30. doi: 10.1007/s00432-016-2190-8. Epub 2016 Jun 17. J Cancer Res Clin Oncol. 2016. PMID: 27316629 Review.

5

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.

Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, Collado Borrell R, Ibañez-Garcia S, Lallana Sainz E, Lobato Matilla E, Lorenzo-Pinto A, Manrique-Rodriguez S, Fernandez-Llamazares CM, Marzal-Alfaro M, Ribed A, Romero Jimenez RM, Sarobe Gonzalez C, Herranz A, Sanjurjo M. Chamorro-de-Vega E, et al. Ann Pharmacother. 2016 Nov;50(11):901-908. doi: 10.1177/1060028016659306. Epub 2016 Jul 20. Ann Pharmacother. 2016. PMID: 27422641

6

Eosinophilia secondary to lenalidomide therapy.

Escudero-Vilaplana V, Osorio-Prendes S, Collado-Borrell R, González-Arias E, Sanjurjo-Sáez M. Escudero-Vilaplana V, et al. J Clin Pharm Ther. 2018 Apr;43(2):273-275. doi: 10.1111/jcpt.12611. Epub 2017 Aug 17. J Clin Pharm Ther. 2018. PMID: 28833364

7

Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities.

González J, Quiroga M, Escudero-Vilaplana V, Collado-Borrell R, Herranz-Alonso A, Sanjurjo Sáez M. González J, et al. Expert Opin Drug Saf. 2018 Jun;17(6):553-572. doi: 10.1080/14740338.2018.1477937. Epub 2018 May 28. Expert Opin Drug Saf. 2018. PMID: 29781751 Review.

8

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey.

Collado-Borrell R, Escudero-Vilaplana V, Calles A, Garcia-Martin E, Marzal-Alfaro B, Gonzalez-Haba E, Herranz-Alonso A, Sanjurjo-Saez M. Collado-Borrell R, et al. J Med Internet Res. 2018 Oct 23;20(10):e11006. doi: 10.2196/11006. J Med Internet Res. 2018. PMID: 30355554 Free PMC article.

9

Design of the functional requirements of a smartphone app for patients receiving oral antineoplastic agents: The e-OncoSalud® app.

Collado-Borrell R, Escudero-Vilaplana V, Ribed A, Anglada-Martínez H, Martín-Conde M, Herranz-Alonso A, Codina-Jané C, Sanjurjo-Sáez M. Collado-Borrell R, et al. J Oncol Pharm Pract. 2020 Jan;26(1):105-115. doi: 10.1177/1078155219840419. Epub 2019 Apr 7. J Oncol Pharm Pract. 2020. PMID: 30955468

10

Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.

Escudero-Vilaplana V, Revuelta-Herrero JL, Collado-Borrell R, Marzal-Alfaro B, Gimenez-Manzorro A, Herranz-Alonso A, Sanjurjo-Saez M. Escudero-Vilaplana V, et al. Expert Opin Drug Saf. 2019 Sep;18(9):861-868. doi: 10.1080/14740338.2019.1641197. Epub 2019 Jul 15. Expert Opin Drug Saf. 2019. PMID: 31282227

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page